MedTrace Logo

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

NCT04664725 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-12-11

No results posted yet for this study

Summary

The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion

Conditions

  • Prostate Cancer Patients

Interventions

DRUG

Repaglinide, Bupropion and SHR3680

Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Weiqing Han, Ph.D · Hunan Cancer Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-01-31
Completion
2021-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04664725 on ClinicalTrials.gov